Stockscreener 앱 받기
9.45
0.32%
-0.03
시장 영업 전:
9.65
0.20
+2.12%
전일 마감가:
$9.48
열려 있는:
$9.46
하루 거래량:
1.44M
Relative Volume:
0.68
시가총액:
$1.42B
수익:
-
순이익/손실:
$-738.82M
주가수익비율:
-1.3577
EPS:
-6.9602
순현금흐름:
$-610.15M
1주 성능:
+7.88%
1개월 성능:
-11.52%
6개월 성능:
-2.48%
1년 성능:
-38.76%
1일 변동 폭
$9.43
$9.92
1주일 범위
$8.22
$9.92
52주 변동 폭
$7.48
$18.57
바이오헤이븐 Stock (BHVN) Company Profile
명칭
Biohaven Ltd
전화
203-404-0410
주소
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
9.45 | 1.43B | 0 | -738.82M | -610.15M | -6.9602 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
바이오헤이븐 Stock (BHVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 개시 | Canaccord Genuity | Buy |
| 2026-02-06 | 개시 | Goldman | Buy |
| 2026-01-21 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-12-03 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-11-06 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-09-17 | 개시 | Citigroup | Buy |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-05-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-09-16 | 개시 | Jefferies | Buy |
| 2024-09-04 | 개시 | Bernstein | Outperform |
| 2024-07-24 | 개시 | Morgan Stanley | Overweight |
| 2024-02-16 | 개시 | RBC Capital Mkts | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2023-12-22 | 개시 | H.C. Wainwright | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-01-24 | 개시 | SVB Securities | Outperform |
| 2023-01-04 | 개시 | JP Morgan | Overweight |
| 2022-12-02 | 개시 | BTIG Research | Buy |
| 2022-10-26 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | 개시 | Piper Sandler | Overweight |
| 2022-08-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-05-11 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-10 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-08-03 | 재확인 | Canaccord Genuity | Buy |
| 2021-03-11 | 개시 | UBS | Buy |
| 2020-12-15 | 개시 | H.C. Wainwright | Buy |
| 2020-04-17 | 개시 | Cowen | Outperform |
| 2020-02-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2019-11-22 | 개시 | Wedbush | Outperform |
| 2019-06-25 | 재확인 | Canaccord Genuity | Buy |
| 2019-05-06 | 개시 | Goldman | Buy |
| 2019-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | 재확인 | Needham | Buy |
| 2018-07-03 | 재확인 | Needham | Buy |
| 2018-07-02 | 재확인 | Needham | Buy |
| 2018-04-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2018-02-22 | 재확인 | Canaccord Genuity | Buy |
| 2017-12-15 | 개시 | Canaccord Genuity | Buy |
| 2017-10-03 | 재확인 | Needham | Buy |
모두보기
바이오헤이븐 주식(BHVN)의 최신 뉴스
Trading Systems Reacting to (BHVN) Volatility - Stock Traders Daily
BofA Securities Maintains Biohaven(BHVN.US) With Hold Rating, Maintains Target Price $12 - Moomoo
BHVN Stock Price, Quote & Chart | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
BTIG Reiterates Biohaven (BHVN) Buy Recommendation - MSN
BHVN Stock Chart | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
[SCHEDULE 13G/A] Biohaven Ltd. Amended Passive Investment Disclosure - Stock Titan
BHVN Stock Price Prediction 2025-2026 | Biohaven Pharmaceutical Holding Co Ltd Forecast - 24/7 Wall St.
Biohaven (BHVN) Narrows Loss and Adds Shelf Registration Is Its Capital Strategy Evolving? - simplywall.st
Biohaven Ltd. (BHVN) Receives a Hold from Bernstein - The Globe and Mail
BHVN Technical Analysis | Trend, Signals & Chart Patterns | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
Morgan Stanley Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $18 - Moomoo
Morgan Stanley Cuts Price Target on Biohaven to $18 From $21, Keeps Overweight Rating - Moomoo
TradingKey - TradingKey
Biohaven Ltd. Stock 12‑Month Price Target Cut to $22.19, Implies 141% Upside - TradingView
Biohaven (BHVN) Valuation Check After Q1 Results And New Shelf Registration - simplywall.st
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright reiterates Biohaven stock rating ahead of trial By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Biohaven stock rating ahead of trial - Investing.com
Biohaven: Hold Rating Reiterated as Clinical and Competitive Uncertainties Persist; Price Target Maintained at $10 - TipRanks
H.C. Wainwright Maintains Biohaven(BHVN.US) With Hold Rating, Maintains Target Price $10 - Moomoo
How Biohaven Ltd. (BHVN) Affects Rotational Strategy Timing - Stock Traders Daily
MSN Money - MSN
Biohaven Ltd. (BHVN) upgraded to buy: Here's why - MSN
Biohaven (BHVN) Is Up 9.1% After Narrower Q1 Loss And New Mixed Shelf RegistrationWhat's Changed - Yahoo Finance
Biohaven Warns of Broad Operational, Financial and Market Risks, Affirms Overall Risk Profile Matches Prior 10-K Disclosures - TipRanks
Biohaven Expands At-The-Market Equity Offering Program - TipRanks
Biohaven (NYSE: BHVN) adds $350.0 million at-the-market share program - Stock Titan
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why - Yahoo! Finance Canada
Biohaven: Buy Rating Reiterated as Analyst Sees Multiple Pipeline Catalysts and Maintains $21 Price Target - TipRanks
RBC Capital Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $22 - Moomoo
A Quick Look at Today's Ratings for Biohaven(BHVN.US), With a Forecast Between $12 to $30 - Moomoo
Biohaven Ltd. Q1 2026 Financial Report: Key Highlights, Financial Statements, and Business Overview - Minichart
RBC Cuts Price Target on Biohaven to $22 From $23, Keeps Outperform, Speculative Risk - marketscreener.com
A Look At Biohaven (BHVN) Valuation After Narrower Q1 Loss And New Pivotal Trial And Funding Plans - Yahoo Finance
BofA Securities Maintains Biohaven(BHVN.US) With Hold Rating, Cuts Target Price to $12 - Moomoo
Biohaven Price Target Trimmed to $12 as Analyst Maintains Hold Amid Balanced Pipeline Upside and Financing Risks - TipRanks
MSN - MSN
Biohaven (BHVN) Is Up 5.7% After Narrower Q1 Loss And Pivotal Trial Plans – Has The Bull Case Changed? - simplywall.st
Biohaven Shareholders Back Board, Auditor and Executive Pay - TipRanks
Biohaven files for offering of up to $350 million common sharesSEC filing - marketscreener.com
Biohaven Ltd. (NYSE: BHVN) expands ATM program to $350M for common shares - Stock Titan
Biohaven (NYSE: BHVN) trims Q1 2026 loss and raises $178.9M - Stock Titan
Biohaven Pharma (BHVN) files mixed shelf - StreetInsider
Biohaven Ltd files for mixed shelf offering size not disclosedSEC filing - marketscreener.com
Biohaven Ltd. (NYSE: BHVN) files shelf to register shares, debt and warrants - Stock Titan
Earnings Flash (BHVN) Biohaven Ltd. Posts Q1 Adjusted Loss $0.69 per Share, Vs. FactSet Est of $-0.83 - Moomoo
Two late-stage readouts due in 2026 as Biohaven cash reaches $351.8M - Stock Titan
Biohaven : Reports Recent Business Developments and First Quarter 2026 Financial Results - marketscreener.com
Biohaven Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
바이오헤이븐 (BHVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
1.33%
자본화:
|
볼륨(24시간):